Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. CRA8003-CRA8003 ◽  
Author(s):  
R. S. Herbst ◽  
Y. Sun ◽  
S. Korfee ◽  
P. Germonpré ◽  
N. Saijo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Small Cell ◽  
Phase Iii ◽  
Line Treatment ◽  
Second Line ◽  
Small Cell Lung ◽  
Double Blind ◽  
Phase Iii Trial ◽  
Final Text

CRA8003 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]

Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 7000-7000 ◽  
Author(s):  
R. Jotte ◽  
J. Von Pawel ◽  
D. R. Spigel ◽  
M. A. Socinski ◽  
M. O'Brien ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase Iii ◽  
Line Treatment ◽  
Second Line ◽  
Small Cell Lung ◽  
Phase Iii Trial

scholarly journals Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer

2008 ◽  
Vol 98 (10) ◽  
pp. 1608-1613 ◽  
Author(s):  
L Paz-Ares ◽  
H Ross ◽  
M O'Brien ◽  
A Riviere ◽  
U Gatzemeier ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase Iii ◽  
Line Treatment ◽  
Second Line ◽  
Small Cell Lung ◽  
Phase Iii Trial
Sign in / Sign up

Export Citation Format

Share Document